In order to examine how hormones and biological sex influence the production of 31 different immune cell types, the team analysed blood samples from 283 individuals between the ages of six and 84 years.
Of these, 203 were cisgender females and cisgender males, including post-menopausal women receiving hormone replacement therapy (HRT). They also analysed samples, taken between 2016 and 2020, from 80 transgender females and males receiving gender-affirming or puberty suppressing hormone treatments.
The results indicated that cisgender females (XX chromosomal background) have higher levels of specific white blood cells, known as class-switched memory B cells, than cisgender males (XY chromosomal background).
Class-switched memory B cells, which are a major component of the immune system, have undergone a process known as ‘class-switching’ that makes them highly efficient at fighting infections that the body has encountered before. However, these ‘specially trained’ B cells may also lead to more severe symptoms if the person has an autoimmune disorder, where a person’s immune system attacks their own healthy tissues.
Crucially, researchers found that there were only differences between the sexes when comparing those who had completed puberty, but not yet gone through the menopause (in the case of cisgender females). This finding and the fact that B cells can interact with oestrogen, which lower in females before puberty and after menopause, may indicate that oestrogen is associated with the increase in class-switched memory B cells.
Professor Coziana Ciurtin, principal investigator of the study and from the Centre for Adolescent Rheumatology at UCL, said: “Our findings could partially explain the sex differences we see in many infectious diseases, vaccine responses, and autoimmune disorders, and add to the growing evidence that sex and gender are critical factors to be considered in immunological studies.”
The authors say that despite the differences in class-switched memory B cells observed in the different groups, it is not possible to conclude that these differences are ‘good’ or ‘bad’ in terms of overall health. Future research would be needed to address this.
The team found that in transgender males (XX chromosomal background) receiving treatment to block their production of oestrogen, levels of class-switched memory B cells were significantly reduced when compared to cisgender females of the same age. These levels were comparable to those seen in cisgender males.
However, when they analysed samples from transgender females (XY chromosomal background) who were taking oestrogen to affirm their gender, their levels of class-switched memory B cells were comparable with those seen in cisgender males.
Professor Lucy Wedderburn from the UCL Great Ormond Street Institute of Child Health and Director of the Centre for Adolescent Rheumatology at UCL, said: “The X chromosome carries numerous genes that are important for human immune responses, so it was critical to find out whether the effects of oestrogen would be the same in cisgender females and transgender males with two X chromosomes, versus cisgender males and transgender females with only one X chromosome.
“This data from our Centre demonstrates that sex hormones and chromosomes work in tandem to impact immune responses, with oestrogen only influencing the frequency of class-switched memory B cells in individuals with an XX chromosomal background.”
The research highlights the need for further high-quality, long-term studies to examine the impact of hormonal treatment on infection and autoimmunity risk across a range of sex chromosomal backgrounds and stages of life.
Dr Hannah Peckham, first author of the study from UCL Division of Medicine, UCL Great Ormond Street Institute of Child Health, and the Centre for Adolescent Rheumatology at UCL, said. “Our study demonstrates that improvements in diversity and inclusion practices within medical research will not only advance our scientific understanding of sex-biases in disease outcomes, but potentially shed light on novel strategies for personally tailored healthcare and potentially mitigate against health inequalities.”
The study was funded by Versus Arthritis, Great Ormond Street Hospital Children’s Charity, Bart’s Charity, the Medical Research Foundation, NIHR UCLH Biomedical Research Centre and the NIHR Great Ormond Street Hospital Biomedical Research Centre.